Dermatophagoides farinae allergen proteins (Der f allergens)

Dermatophagoides farinae allergen proteins are a complex mixture of antigenic proteins derived from the American house dust mite, which are primary drivers of indoor allergic diseases worldwide (WHO/IUIS Allergen Nomenclature Database, 2024). The most clinically significant components are Der f 1, a cysteine protease that can degrade tight junctions in respiratory epithelium, and Der f 2, which mimics the MD-2 protein to facilitate Toll-like receptor 4 signaling (UniProt Consortium, 2024). These proteins trigger the production of allergen-specific IgE antibodies, leading to mast cell degranulation and the subsequent symptoms of allergic rhinitis, conjunctivitis, and asthma (Galli et al., Nature, 2008). In the pharmaceutical industry, these allergens are utilized as therapeutic targets in allergen-specific immunotherapy (AIT), where they are administered to patients to induce immune tolerance (Akdis & Akdis, JACI, 2014). The mechanism involves the induction of regulatory T cells and the production of protective IgG4 antibodies, which compete with IgE for allergen binding (Durham & Shamji, JACI, 2023). Standardized extracts of these proteins are FDA-approved for sublingual administration to treat mite-induced allergic rhinitis (FDA, Odactra Prescribing Information, 2017). This therapeutic approach aims to modify the underlying disease process rather than just managing symptoms.

Other names

American house dust mite allergensDer f proteinsHouse dust mite allergens (D. farinae)Dermatophagoides farinae extract

Induction of peripheral T-cell tolerance, stimulation of regulatory T cells (Tregs), and promotion of allergen-specific IgG4 antibody production to block IgE-mediated responses (Akdis & Akdis, JACI, 2014; Durham & Shamji, JACI, 2023).